Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 8 results for "lacosamide"

Market Research Report on Global and Chinese Lacosamide Indust...

is a professional and in-depth market survey on Global and Chinese Lacosamide industry. The report firstly reviews the basic information of Lacosamide including its classification, application and manufacturing technology; The report then explores ..., 1 month ago

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Revision: 16, Authorised

This is a summary of the European public assessment report (EPAR) for Vimpat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 month ago

INDOCO REMEDIES : Patent Issued for Process for Preparation of Lacosamide and Some N-Benzyl-Propanamide Intermediate Derivatives

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Alexandria, Virginia , by NewsRx journalists, a patent by the inventors Rajadhyaksha, Mangesh Narayan ( Mumbai , IN); Nair, Ranjeet ( Mumbai , IN); ...
 4 Traders6 days ago

Class 2 Drug Alert (Action Within 48 Hours): Vimpat 150mg Tablets - Lacosamide - OPD Laboratories Limited - EL (13)A/01

DRUG ALERT CLASS 2 MEDICINES RECALL Action within 48 hours Pharmacy, Clinic and Wholesaler level recall 08 January 2013 EL (13)A/01 Our ref: MDR 03-01/13 Dear Healthcare Professional, OPD Laboratories Limited Vimpat 150mg Tablets (Lacosamide) ...
 MHRA1 month ago

UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances

UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient solutions: brivaracetam, epratuzumab and ...
 European Pharmaceutical Review4 days ago

US and EU regulatory filings for UCB's antiepileptic brivaracetam

Belgium's largest pharma company UCB (Euronext Brussels: UCB) today announced regulatory filings in the USA and the European Union for its investigational antiepileptic drug brivaracetam. However, the company's shares dipped 1.6% to 68.58 euros by ...
 Pharma Letter1 month ago

Exalief (Eslicarbazepine Acetate) Soon to be Available in Russia as a Once Daily Adjunctive Treatment of Partial Onset Seizures in Adults

/PRNewswire/ -- PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Novel, anti-epilepsy treatment Exalief(R) will soon be available in Russia. (Exalief is also marketed under the trade name Zebinix in Europe). Once-daily ...
 Individual.com1 month ago
Pharma Letter

UCB appoints Jean-Christophe Tellier as chief executive

Belgian drugmaker UCB has replaced chief executive Roch Doliveux with Jean-Christophe Tellier. Mr Tellier will also be chairman of the executive committee and a member of the board of directors. His predecessor, Roch Doliveux, stepped down on ...
 Pharma Letter1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less